BOLERO-2: EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER REFRACTORY TO LETROZOLE OR ANASTROZOLE

被引：0
|
作者：
Campone, Mario [1 ]
Piccart, Martine [2 ]
Pritchard, Kathleen I. [3 ,4 ]
Xu, Cindy [5 ]
Gnant, Michael [6 ]
Neven, Patrick [7 ]
Pistilli, Barbara [8 ]
Shtivelband, Mikhail [9 ]
Provencher, Louise [10 ]
Masuda, Norikazu [11 ]
El-Hashimy, Mona [5 ]
Vittori, Luc [12 ]
Sahmoud, Tarek [5 ]
Baselga, Jose [13 ]
Hortobagyi, Gabriel N. [14 ]
机构：
[1] Ctr Reg Rene Gauducheau, St Herblain, France
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Novartis Pharmaceut, Florham Pk, NJ USA
[6] Med Univ Vienna, Vienna, Austria
[7] Catholic Univ Louvain, UZ Leuven, B-3000 Louvain, Belgium
[8] Macerata Hosp, Dept Oncol, Macerata, MC, Italy
[9] Ironwood Canc & Res Ctr, Chandler, AZ USA
[10] Hop St Sacrement, Quebec City, PQ, Canada
[11] Osaka Natl Hosp, Osaka, Japan
[12] Novartis Pharma AG, Basel, Switzerland
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/j.breast.2011.08.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [41] Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study
    Campone, Mario
    Bachelot, Thomas
    Gnant, Michael
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Noguchi, Shinzaburo
    Shtivelband, Mikhail
    Pritchard, Kathleen I.
    Provencher, Louise
    Burris, Howard A., III
    Hart, Lowell
    Melichar, Bohuslav
    Hortobagyi, Gabriel N.
    Arena, Francis
    Baselga, Jose
    Panneerselvam, Ashok
    Heniquez, Aurelia
    El-Hashimyt, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Piccart, Martine
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (12) : 2621 - 2632
  • [42] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Denise A. Yardley
    Shinzaburo Noguchi
    Kathleen I. Pritchard
    Howard A. Burris
    José Baselga
    Michael Gnant
    Gabriel N. Hortobagyi
    Mario Campone
    Barbara Pistilli
    Martine Piccart
    Bohuslav Melichar
    Katarina Petrakova
    Francis P. Arena
    Frans Erdkamp
    Wael A. Harb
    Wentao Feng
    Ayelet Cahana
    Tetiana Taran
    David Lebwohl
    Hope S. Rugo
    Advances in Therapy, 2013, 30 : 870 - 884
  • [43] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    A Barnadas
    M Gil
    S González
    I Tusquets
    M Muñoz
    A Arcusa
    L Prieto
    M Margelí-Vila
    A Moreno
    British Journal of Cancer, 2009, 100 : 442 - 449
  • [44] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    Barnadas, A.
    Gil, M.
    Gonzalez, S.
    Tusquets, I.
    Munoz, M.
    Arcusa, A.
    Prieto, L.
    Margeli-Vila, M.
    Moreno, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (03) : 442 - 449
  • [45] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Yardley, Denise A.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Baselga, Jose
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Campone, Mario
    Pistilli, Barbara
    Piccart, Martine
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Erdkamp, Frans
    Harb, Wael A.
    Feng, Wentao
    Cahana, Ayelet
    Taran, Tetiana
    Lebwohl, David
    Rugo, Hope S.
    ADVANCES IN THERAPY, 2013, 30 (10) : 870 - 884
  • [46] Final progression-free survival analysis of BOLERO-2: a phase Ill trial of everolimus for postmenopausal women with advanced breast cancer
    Piccart, M.
    Baselga, J.
    Noguchi, S.
    Burris, H.
    Gnant, M.
    Hortobagyi, G.
    Mukhopadhyay, P.
    Taran, T.
    Sahmoud, T.
    Rugo, H.
    CANCER RESEARCH, 2012, 72
  • [47] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [48] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [49] Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial
    Smith, I
    Dowsett, A
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S6 - S6
  • [50] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
12345